More News

Bausch + Lomb Launches Biotrue Lubricating Eye Drops and Eyelid Wipes
Bausch + Lomb Launches Biotrue Lubricating Eye Drops and Eyelid Wipes

Bausch + Lomb announced July 12 the US launch of its Biotrue lubricating eye drops and eyelid cleansing wipes. The company, a division of Canada’s Bausch Health, said both products are preservative...

Topcon Acquires Visia  in Move to Target Anterior Segment, Myopia Markets
Topcon Acquires Visia in Move to Target Anterior Segment, Myopia Markets

Tokyo-based Topcon Healthcare announced July 14 that it had acquired Visia Imaging Srl, an anterior segment device and software manufacturer in Florence, Italy. Financial details were not disclosed...

Select US FDA Approvals and Clearances in June 2021
Select US FDA Approvals and Clearances in June 2021

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in June 2021, according to the agency’s database. IDx, now Digital Diagnostics, added DICOM compat...

US FDA Gives iSTAR Green Light for Pivotal Trial  of MINIject MIGS Device
US FDA Gives iSTAR Green Light for Pivotal Trial of MINIject MIGS Device

Belgium-based iSTAR Medical announced July 15 that the US FDA had given it the green light to begin a pivotal trial for its MINIject device in primary open-angle glaucoma. The STAR-V study will inv...

Sight Sciences Leads Latest Ophthalmic Fundraising with $240 Million IPO
Sight Sciences Leads Latest Ophthalmic Fundraising with $240 Million IPO

Sight Sciences, based in Menlo Park, California, led recent fundraising efforts by ophthalmic companies, with an upsized initial public offering of $240 million. Funding for the past four weeks tot...

Alcon Reports Milestone of 2 Million Cataract Surgeries Using ORA System
Alcon Reports Milestone of 2 Million Cataract Surgeries Using ORA System

Alcon announced June 16 that its Optiwave Refractive Analysis (ORA) System had reached 2 million cases worldwide. The system is composed of an intraoperative wavefront aberrometer and cloud-based A...

RxSight Files Paperwork for $100 Million IPO in US
RxSight Files Paperwork for $100 Million IPO in US

RxSight, of Aliso Viejo, California, filed paperwork with the SEC on July 9 for a $100 million initial public offering of common stock. The company, which developed the RxSight Light Adjustable Len...

Rayner’s Plan to Become Global Ophthalmology Leader Gains Financial Backing of CVC Capital
Rayner’s Plan to Become Global Ophthalmology Leader Gains Financial Backing of CVC Capital

IOL company Rayner’s aggressive plans for global expansion in the ophthalmology market have gained the backing of private equity firm CVC Capital, which acquired a majority interest in Rayner from ...

Osmotica Raises Up  to $170 Million for Marketing Upneeq by Selling Legacy Products
Osmotica Raises Up to $170 Million for Marketing Upneeq by Selling Legacy Products

Osmotica Pharmaceuticals reported June 25 that Alora Pharmaceuticals had agreed to acquire its portfolio of legacy products and its Marietta, Georgia, manufacturing facility, while Osmotica would r...

Emerging Companies Pursuing Ophthalmic Indications, July 2021
Emerging Companies Pursuing Ophthalmic Indications, July 2021

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About AAVantgarde Bio Milan, Italy The company is developing gene therapies...

4DMT to Continue with 4D-110 in Choroideremia after Roche Terminates Collaboration
4DMT to Continue with 4D-110 in Choroideremia after Roche Terminates Collaboration

4D Molecular Therapeutics (4DMT) reported June 24 that Roche had terminated its collaboration and licensing agreement for gene therapy candidate 4D-110 in choroideremia, effective Sept. 26, 2021. 4...

Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growth
Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growth

Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next five years, as companies commercialize more devices designed to meet t...

Indian Surgeons See Spike in Fungal Eye Infections in COVID-19 Patients
Indian Surgeons See Spike in Fungal Eye Infections in COVID-19 Patients

India has seen a surge of mucormycosis, or black fungus, as part of a second wave of COVID-19 that began in March and nearly crippled the country at its worst in mid-May. Eye surgeons have been see...

Weekly Industry Poll, July 2021
Weekly Industry Poll, July 2021

July 2021 Ophthalmic News Briefs
July 2021 Ophthalmic News Briefs

Johnson & Johnson Vision announced June 14 the availability of its TECNIS Synergy and TECNIS Synergy Toric II lenses in the US and Canada. Both lenses gained US approval in April, and the Synergy T...

Sight Sciences Upsizes IPO to $240 Million
Sight Sciences Upsizes IPO to $240 Million

Sight Sciences upsized its initial public offering by 43 percent on July 15, raising $240 million by offering 10 million shares at $24. In addition, the Menlo Park, California, company has granted ...

Topcon Acquires Visia in Move to Target Anterior Segment, Myopia Markets
Topcon Acquires Visia in Move to Target Anterior Segment, Myopia Markets

Tokyo-based Topcon Healthcare announced July 14 that it had acquired Visia Imaging Srl, an anterior segment device and software manufacturer in Florence, Italy. Financial details were not disclosed...

US FDA Gives iSTAR Green Light for Pivotal Trial of MINIject MIGS Device
US FDA Gives iSTAR Green Light for Pivotal Trial of MINIject MIGS Device

Belgium-based iSTAR Medical announced July 15 that the US FDA had given it the green light to begin a pivotal trial for its MINIject device in primary open-angle glaucoma. The STAR-V study will inv...

Bausch + Lomb Launches Biotrue Lubricating Eye Drops and Eyelid Wipes
Bausch + Lomb Launches Biotrue Lubricating Eye Drops and Eyelid Wipes

Bausch + Lomb announced July 12 the US launch of its Biotrue lubricating eye drops and eyelid cleansing wipes. The company, a division of Canada’s Bausch Health, said both products are preservative...

Belkin Laser Changes Corporate Name to Belkin Vision
Belkin Laser Changes Corporate Name to Belkin Vision

Belkin Laser, the Israel-based startup developing a one-second, non-invasive glaucoma laser treatment, announced July 8 that it had begun operating under the name Belkin Vision. The company said th...

Dopavision Raises $14.2 Million in Series A for Childhood Myopia System
Dopavision Raises $14.2 Million in Series A for Childhood Myopia System

German company Dopavision, which is developing a light-based digital system to treat childhood myopia, announced July 14 that it had closed a €12 million (US $14.2 million) Series A financing round...

Iveric Bio Prices $100.2 Million Public Offering of Common Stock
Iveric Bio Prices $100.2 Million Public Offering of Common Stock

Iveric Bio, of New York, on July 12 priced an underwritten public offering of 11.7 million shares of its common stock at $8.60 per share, less underwriting discounts and commissions. The company gr...

Kriya Therapeutics Raises $100 Million in Series B to Advance Gene Therapy Pipeline
Kriya Therapeutics Raises $100 Million in Series B to Advance Gene Therapy Pipeline

Kriya Therapeutics announced July 14 that it had closed a $100 million Series B financing to support its gene therapy pipeline, including programs in geographic atrophy and uveitis. The company, wi...

Pixium Raises $9.5 Million in Private Placement, Mainly in the US
Pixium Raises $9.5 Million in Private Placement, Mainly in the US

Pixium Vision announced July 13 that it had reached an agreement with several new health care focused institutional investors for a private placement of shares, with gross proceeds of €8 million (U...

RxSight Files Paperwork for $100 Million IPO in US
RxSight Files Paperwork for $100 Million IPO in US

RxSight, of Aliso Viejo, California, filed paperwork with the SEC on July 9 for a $100 million initial public offering of common stock. The company, which developed the RxSight Light Adjustable Len...

Ophthalmic Industry Leadership Changes at Outlook, Transine, OcuTerra, and Palatin
Ophthalmic Industry Leadership Changes at Outlook, Transine, OcuTerra, and Palatin

Outlook Therapeutics announced July 7 that it had appointed C. Russell Trenary III as president, chief executive officer, and a member of the board of directors. The Islelin, New Jersey, company sa...

AMA Approves New Category III CPT Code for EyePoint’s Dexycu
AMA Approves New Category III CPT Code for EyePoint’s Dexycu

EyePoint Pharmaceuticals announced July 1 that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel had accepted a new Category III CPT code, 0X78T, for the a...

Sight Sciences Sets Terms for $150 Million IPO
Sight Sciences Sets Terms for $150 Million IPO

Sight Sciences filed SEC paperwork July 8 indicating that it planned to raise $150 million in an initial public offering of 6.98 million shares of common stock at a price range of $20 to $23. The M...

LHON Patients Treated with Lumevoq in Both Eyes See 12-Letter Vision Gain in Latest Trial
LHON Patients Treated with Lumevoq in Both Eyes See 12-Letter Vision Gain in Latest Trial

Paris-based GenSight Biologics reported June 30 that its third Phase III trial for Lumevoq showed bilateral injections of the gene therapy candidate provided bigger improvement in visual acuity tha...

Teva, Bioeq Form Commercial Partnership for Lucentis Biosimilar Candidate
Teva, Bioeq Form Commercial Partnership for Lucentis Biosimilar Candidate

Teva Pharmaceutical Industries and Bioeq announced June 28 that they had entered into a strategic partnership for the exclusive commercialization of Bioeq’s FYB201, a biosimilar candidate to Lucent...

Regenerative Patch Sees Positive Results in Trial of RPE Implant in Dry AMD
Regenerative Patch Sees Positive Results in Trial of RPE Implant in Dry AMD

Regenerative Patch Technologies announced June 28 that it had seen long-term survival of implanted stem cell-derived retinal pigmented epithelial (RPE) cells in a Phase I/IIa trial of the company’s...

AAO, ASCRS Describe ‘Chaos’ as Aetna Begins Requiring Cataract Surgery Pre-authorization
AAO, ASCRS Describe ‘Chaos’ as Aetna Begins Requiring Cataract Surgery Pre-authorization

Aetna’s new requirement for prior authorization of all cataract surgeries took effect July 1 over strong opposition from the American Academy of Ophthalmology (AAO) and American Society of Cataract...

Rayner’s Plan to Become Global Ophthalmology Leader Gains Backing of CVC Capital
Rayner’s Plan to Become Global Ophthalmology Leader Gains Backing of CVC Capital

IOL company Rayner’s aggressive plans for global expansion in the ophthalmology market have gained the backing of private equity firm CVC Capital, which acquired a majority interest in Rayner from ...

Ranibizumab Biosimilar Candidate Byooviz Gains Positive CHMP Opinion
Ranibizumab Biosimilar Candidate Byooviz Gains Positive CHMP Opinion

Samsung Bioepis and Biogen reported June 25 that they had received a positive opinion from the European Medicines Agency’s advisory committee for their ranibizumab biosimilar, Byooviz. Byooviz beco...

US FDA Accepts BLA for Genentech’s Port Delivery System with Ranibizumab for Wet AMD
US FDA Accepts BLA for Genentech’s Port Delivery System with Ranibizumab for Wet AMD

Genentech announced June 24 that the US FDA had accepted the company’s biologics license application (BLA), under priority review, for its Port Delivery System with ranibizumab (PDS) for the treatm...

US FDA Accepts IND for Phase IIb Trial of Nanoscope Gene Therapy Candidate for RP
US FDA Accepts IND for Phase IIb Trial of Nanoscope Gene Therapy Candidate for RP

Nanoscope Therapeutics announced June 23 that its investigational new drug application (IND) is open for a Phase IIb clinical trial of MCO-010, an ambient-light-activatable optogenetic monotherapy ...

J&J Vision’s TECNIS Synergy and Synergy Toric II Available in the US, Canada
J&J Vision’s TECNIS Synergy and Synergy Toric II Available in the US, Canada

Johnson & Johnson Vision announced June 14 the availability of its TECNIS Synergy and TECNIS Synergy Toric II lenses in the US and Canada. Both lenses gained US approval in April, and the Synergy T...

Editas Enrolls First Pediatric Cohort in Trial of LCA10 Gene Therapy Candidate
Editas Enrolls First Pediatric Cohort in Trial of LCA10 Gene Therapy Candidate

Editas Medicine announced June 23 that centers are enrolling the first of two planned pediatric cohorts in the Phase I/II BRILLIANCE clinical trial of its EDIT-101 gene therapy candidate for Leber ...

Osmotica Raises Up to $170 Million for Marketing Upneeq by Selling Legacy Business to Alora
Osmotica Raises Up to $170 Million for Marketing Upneeq by Selling Legacy Business to Alora

Osmotica Pharmaceuticals reported June 25 that Alora Pharmaceuticals had agreed to acquire its portfolio of legacy products and its Marietta, Georgia, manufacturing facility, while Osmotica would r...

4DMT to Continue with 4D-110 in Choroideremia after Roche Terminates Collaboration
4DMT to Continue with 4D-110 in Choroideremia after Roche Terminates Collaboration

4D Molecular Therapeutics (4DMT) reported June 24 that Roche had terminated its collaboration and licensing agreement for gene therapy candidate 4D-110 in choroideremia, effective Sept. 26, 2021. 4...

Gyroscope Will Collaborate with Children’s Medical Research Institute in Australia on Gene Therapy Capsids
Gyroscope Will Collaborate with Children’s Medical Research Institute in Australia on Gene Therapy Capsids

UK-based Gyroscope Therapeutics announced June 22 that it had begun a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop next-generation clinical capsi...

OcuTerra Appoints David J. Tanzer, MD, as Chief Medical Officer
OcuTerra Appoints David J. Tanzer, MD, as Chief Medical Officer

Boston-based OcuTerraTherapeutics, formerly SciFluor Life Sciences, announced June 25 that it had appointed David J. Tanzer, MD, as chief medical officer and executive vice president, clinical and ...

Indian Ophthalmologists See Spike in Fungal Eye Infections in COVID-19 Patients
Indian Ophthalmologists See Spike in Fungal Eye Infections in COVID-19 Patients

India has seen a surge of mucormycosis, or black fungus, as part of a second wave of COVID-19 that began in March and nearly crippled the country at its worst in mid-May. Eye surgeons have been see...

Implandata Reports Latest CE Marking Milestone for Eyemate-SC IOP Sensor
Implandata Reports Latest CE Marking Milestone for Eyemate-SC IOP Sensor

German company Implandata Ophthalmic Products announced June 21 that its Eyemate-SC biosensor—a less invasive, improved version of its predecessor implant—had gained CE marking and will be launched...

Santen’s Verkazia Gains US Approval for Vernal Keratoconjunctivitis
Santen’s Verkazia Gains US Approval for Vernal Keratoconjunctivitis

US-based Santen Inc. reported June 24 that Verkazia had gained US approval for the treatment of vernal keratoconjunctivitis in children and adults. Santen Inc. is a subsidiary of Japan-based Santen...

Rayner Acquires Indian Distributor for Direct Sales Presence
Rayner Acquires Indian Distributor for Direct Sales Presence

UK-based IOL maker Rayner announced June 16 that it had acquired its longtime, exclusive Indian distributor, Surgicon Healthcare Pvt Limited, for an undisclosed price. Rayner said the acquisition g...

PanOptica Licenses to Zhaoke Investigational Daily Drop for Retinal Disease
PanOptica Licenses to Zhaoke Investigational Daily Drop for Retinal Disease

PanOptica of Mount Arlington, New Jersey, announced June 17 that it had licensed to Zhaoke Ophthalmology exclusive rights for the development and commercialization of PanOptica’s PAN-90806 in Great...

Tarsus’ TP-03 for Demodex Blepharitis Meets All Endpoints in First of Two Pivotal Trials
Tarsus’ TP-03 for Demodex Blepharitis Meets All Endpoints in First of Two Pivotal Trials

Tarsus Pharmaceuticals announced on June 21 that all primary and secondary endpoints were met in its pivotal Phase IIb/III SATURN-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) in ...

Oyster Point Enrolls First Subject in Phase II Trial of its Varenicline Nasal Spray for NK
Oyster Point Enrolls First Subject in Phase II Trial of its Varenicline Nasal Spray for NK

Oyster Point Pharma announced June 21 that it had enrolled the first subject in its OLYMPIA Phase II trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 neurotrophic keratopathy (...

Phase I Results Show Glaucoma Candidate Delivered Intranasally is Safe, Noveome Says
Phase I Results Show Glaucoma Candidate Delivered Intranasally is Safe, Noveome Says

Preliminary results of a Phase I open-label clinical trial found that ST266 delivered intranasally in glaucoma suspect patients was safe, Noveome Biotherapeutics announced June 7. ST266 is a novel ...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more